Photo of Brian Hasinoff

Brian Hasinoff

Office:University of Manitoba

Research: Dr. Hasinoff investigates the cardioprotective bisdioxopiperazine antioxidant drug dexrazoxane (ICRF-187) and its ability to prevent the dose-limiting cardiotoxicity caused by the antitumor anthracycline doxorubicin, which causes myocardial tissue damage through iron-mediated oxygen free radical production. He also investigates the ability bisdioxopiperazines to catalytically inhibit DNA topoisomerase II. The mechanism of action of topoisomerase II is being studied using dexrazoxane and other bisdioxopiperazines as probes.